Glenmark Report Results of FabiFlu (favipiravir) in P-III Clinical Study for Patients with Mild to Moderate COVID-19
Shots:
- The P-III study assessing the efficacy and safety of Favipiravir + SSC vs SCC in 150 mild to moderate patients- randomized within a 48hour window of testing RT-PCR positive for COVID-19
- Results: P-III study the improvement in 1EPs with 28.6% faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of the virus. 2EPs include 40% faster achievement of clinical cure- patients receiving clinical cure @day4 (69.8% vs 44.9%) median time to first-time use of oxygen in clinically deteriorated (5days vs 2days)
- on June 20- 2020- FabiFlu has received DCGI’s approval- making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. Glenmark has initiated PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients
Ref: Glenmark | Image: IndiaTVNews
Related News: Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
